Featured Research

from universities, journals, and other organizations

Docetaxel Given After Doxorubicin Reduces Recurrence, Study Suggests

Date:
January 8, 2008
Source:
Journal of the National Cancer Institute
Summary:
Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published in the Journal of the National Cancer Institute.

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

Related Articles


Docetaxel has previously been shown to be more effective than doxorubicin (an anthracycline) for treating patients with advanced breast cancer. Therefore, researchers wanted to test it in patients receiving chemotherapy after surgery.

Prudence Francis, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, and colleagues conducted a randomized, controlled phase III trial that compared patients who received doxorubicin-based chemotherapy with and without docetaxel. The trial also examined whether docetaxel should be given after doxorubicin or at the same time. The researchers compared disease-free survival for each treatment.

Overall, patients receiving the docetaxel treatment had an improvement in disease-free survival that was borderline statistically significant. Patients receiving docetaxel after doxorubicin had a five-year disease-free survival rate of 78 percent, compared with 74 percent for those receiving the two drugs at the same time. Patients in the control arm--those who received only doxorubicin-based chemotherapy--had a five-year disease-free survival rate of 73 percent. However, there was no statistically significant difference in overall survival between patients who received docetaxel and those who did not.

"Important differences may be related to doxorubicin and docetaxel scheduling, with sequential, but not concurrent, administration appearing to produce better [disease-free survival] than anthracycline-based adjuvant chemotherapy," the authors write.

Citations: Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, et al. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 -- 98 Randomized Trial. J Natl Cancer Inst 2008; 100:121-133


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Docetaxel Given After Doxorubicin Reduces Recurrence, Study Suggests." ScienceDaily. ScienceDaily, 8 January 2008. <www.sciencedaily.com/releases/2008/01/080108183115.htm>.
Journal of the National Cancer Institute. (2008, January 8). Docetaxel Given After Doxorubicin Reduces Recurrence, Study Suggests. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2008/01/080108183115.htm
Journal of the National Cancer Institute. "Docetaxel Given After Doxorubicin Reduces Recurrence, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/01/080108183115.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins